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Abstract
Background: The objective of this study was to document the worldwide
decline of dracunculiasis (Guinea worm disease, GWD) burden, expressed as
disability-adjusted life years (DALYs), from 1990 to 2016, as estimated in the
Global Burden of Disease study 2016 (GBD 2016). While the annual number of
cases of GWD have been consistently reported by WHO since the 1990s, the
burden of disability due to GWD has not previously been quantified in GBD.
Methods: The incidence of GWD was modeled for each endemic country using
annual national case reports. A literature search was conducted to characterize
the presentation of GWD, translate the clinical symptoms into health sequelae,
and then assign an average duration to the infection. Prevalence measures by
sequelae were multiplied by disability weights to estimate DALYs.
Results: The total DALYs attributed to GWD across all endemic countries
(n=21) in 1990 was 50,725 (95% UI: 35,265–69,197) and decreased to 0.9
(95% UI: 0.5–1.4) in 2016. A cumulative total of 12,900 DALYs were attributable
to GWD from 1990 to 2016.
Conclusions: Using 1990 estimates of burden propagated forward, this
analysis suggests that between 990,000 to 1.9 million DALYs have been
averted as a result of the eradication program over the past 27 years.
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Introduction
Dracunculiasis, also known as Guinea worm disease (GWD),
is caused by the parasitic worm Dracunculus medinensis (literally, little dragon from Medina)1. The transmission cycle begins
when Guinea worm larvae are released into common stagnant
sources of surface drinking water (e.g., ponds, lakes, unprotected
shallow wells) where they are consumed by minute aquatic
crustaceans (copepods). In about two weeks, the larvae inside
the copepods develop into the infective stage2. At this time, if
contaminated water is ingested, larvae migrate through the intestinal wall into the connective tissues, where they mature and
mate. Approximately 10–14 months post-infection, a painful,
burning blister is created on the skin. The skin over the blister
sloughs-off in about 48 hours, revealing the skin lesion and the
anterior end of the worm. To relieve the pain, infected persons
immerse the affected body part in water, triggering the worm
to emerge through the skin and expel her larvae and the cycle
begins again2–5.
The subsequent ulcer is painful and can often become infected,
but most individuals recover over a period of weeks to months.
Permanent disability, as well as death, have been documented
but are very rare6. There is no specific chemotherapy for GWD
nor vaccine available. Diagnosis occurs at emergence2 and treatment is limited to case management to avoid secondary bacterial
infections. In the context of eradication programs, the traditional practice of wrapping the worm around a stick as it slowly
emerges has been replaced by wrapping the worm around
a sterile gauze and is augmented with wound management using
sterile bandages, topical antibiotic ointment, and treatment with
anti-inflammatories7.
The global campaign to eradicate Guinea worm began in
1980 at the U.S. Centers for Disease Control and Prevention
(CDC)1. The campaign gained momentum when Guinea worm
eradication was proposed to measure the success of the International
Drinking Water Supply and Sanitation Decade of 1981–19902,8.
The global eradication effort is led by national governments and
communities, with the support of a coalition of partners including The Carter Center, WHO, CDC, UNICEF and other partners
and donors8. To break the cycle of transmission, national Guinea
Worm Eradication Programs implement case detection and
containment, provision of safe water sources, distribution
of filter cloths and pipe filters, water source treatment with
a larvicide (temephos), and health education7.
In 1990, a total of approximately 624,000 cases were reported
globally; in 2016, only 25 cases were reported across four
remaining endemic countries9. If the global campaign is successful, Guinea worm could be the second human disease in history
eradicated by direct public health interventions10. The costly
up-front investment in eradication is often cited as a mechanism to avoid the repeated and ongoing costs of treatment and
prevention11,12. Although there is no consensus on the ideal
methodology to quantify the economic or social benefits of
eradication13, the impact of eradication in terms of alleviating
human suffering is clear12.
The first report of GWD surveillance was released in 198214
and the World Health Assembly resolution WHA39.21 was

endorsed in 1986. The annual number of cases of GWD has been
consistently reported by WHO since the 1990s, but the burden
of disability due to GWD has not previously been quantified
in the Global Burden of Diseases, Injuries, and Risk Factors
Study (GBD). Several village-level studies conducted between
1970 and the mid-1990s have described the clinical presentation
of GWD15, and have quantified economic and productivity losses
due to temporary and long-term disability. Given the historic
accomplishments of global eradication efforts1, as well as the
impetus for continued investment, an estimate of the burden of
GWD comparable to other diseases generated by the GBD 2016
framework is valuable. Disability-adjusted life years (DALYs)
serve as a measure of overall disease burden, expressed as the
number of years lost due to disability or early death. DALYs
estimated by GBD are comparable between countries and
through time; for example, the burden of GWD can be compared
not only to other infectious diseases but chronic conditions as
well16. Further, comparison of estimates of burden from the early
1990s could be used to construct alternative scenarios of the burden
of GWD had the eradication program had not been implemented.
Each disease eradication event (this may be only the second)
provides important data on the economic case for eradication.
Moreover, because simply documenting contemporary DALYs16
can lead to the misplaced interpretation that the case for
continued investment in a disease is diminished, measuring
the benefits of eradication over the entire period of intervention needs a longer-term perspective11,13,16. Here we estimate
DALYs attributable to GWD between 1990 and 2016 as part of
GBD 2016.

Methods
The Global Burden of Disease study
The burden of GWD was estimated for the first time in GBD
201616. GBD produces the only comprehensive DALYs for
333 diseases and injuries, from 1990 to the present, for 195
countries and territories16. A detailed description of GBD 2016
methodology is presented elsewhere17,18. Once the prevalence of
a cause is estimated, data on severity and the occurrence of
particular consequences of disease, or “sequelae,” are used to
determine the proportion of prevalent cases experiencing each
sequela. The sequelae are then matched to health states and
assigned disability weights18. GBD causes are collectively
exhaustive and mutually exclusive.
Data sources. We extracted annual country-level Guinea worm
case data from the Weekly Epidemiological Record (WER),
published by WHO, as detailed in Supplementary File 1. In the
early 1990s, there are years for which annual case data are either
missing or inconsistent with preceding/following annual reports.
Thus, annual case data were reviewed for completeness and
plausibility by comparison with each country’s longitudinal case
data and implausible case reports were excluded (Supplementary
File 1). For example, in the case of Niger, which reported 32,829
cases in 1991 and then 500 in 1992, followed by 25,346 in
1993, the 1992 case data were treated as an outlier. A
literature search using the PubMed database identified peerreviewed publications (see Table 1) that described the clinical
presentation of GWD in terms of symptoms, sequelae, and duration of morbidity among individuals with incident or prevalent
GWD.
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Table 1. Summary of Guinea-worm-related disability data reported in peer-reviewed literature.
Countryref

Year(s)

Number of
communities
(sample size*)

Type of morbidity
reported**

Mean duration

Proportion
affected

Nigeria19

1985

1 village
(444 individuals)

Incapacitation

26 days

93.4%

Nigeria20

1986

1 village
(325 individuals)

Incapacitation

60 days

63%

Nigeria21

1983–1984

295 households

Pain

12.7 weeks

Incapacitation

4.2 weeks

Severe: 58%

Nigeria

1993

2 villages
(982 individuals)

Incapacitation

-

21%

Nigeria23

1971–1975

17 villages
(sample size not
reported)

Pain

--

Severe: 12%
Moderate: 31%
Mild: 57%

Incapacitation

100 days

--

Infection at wound site

--

9.8%

Musculoskeletal problems

--

Pain

4.2 weeks to
7.2 weeks

--

Infection at wound site

10 weeks

17.4%

22

Nigeria15

1971–1974

47 villages
(563 individuals)

Musculoskeletal problems

-

4.6%

Uganda24

1992

43 clusters
(301 women surveyed)

Incapacitation

6 months

40%

Benin25

1987–1989

2 villages
(30 households)

Incapacitation

39–59 days
(across 2 sites)

--

Ghana6

1991

10 villages
(195 individuals)

Pain

12–18 months

28.2%

Incapacitation

--

34%

Ghana26

1973

8 villages
(20 men)

Incapacitation

2.4 to 5.3 weeks

90%

Infection at wound site

--

45%

*Sample size represents total number of individuals with Guinea worm disease (either prevalent or historical cases).
**The term “incapacitation” captures any reports of limited mobility or inability to perform daily tasks, as measurement of
incapacitation was variable across studies. “Musculoskeletal problems” encompasses a wide range of complications affecting joints
and tissues, arthritis, and complications due to infections that could affect the lower limb.

Statistical analysis. The incidence of GWD was then modeled
individually for each country considered endemic in 1990 using
Stata (Release 13; StataCorp; College Station, TX). Incidence
was modeled using either reported case data (where available and
plausible; see Supplementary File 1) or using a Poisson regression over time, by country. For years and locations for which
case data were reported and considered plausible, 1,000 draws
estimating incidence were generated using a beta distribution
of cases and annual national population minus cases to introduce uncertainty, relying on the assumption that national Guinea
Worm Eradication Program data reflect the annual case burden. As
Guinea worm case data were assumed to represent incidence of
new infections, we employed a Poisson regression per country to
predict cases for years and locations for which case data were
missing or excluded, with year as the predictor, and the national
population as the offset. The predicted incidence and standard error
from the Poisson model were then used to generate a random distribution of 1,000 incidence draws for those years with

missing or incomplete case data. For comparison, the analysis
was repeated entirely without exclusion of possible implausible
data.
Calculation of disability-adjusted life years (DALYs). To
convert estimates of prevalence into quantifiable and comparable
measures of disability, GBD first generates estimates of years
lived with disability (YLDs), which for GWD are the product of
prevalence and a disability weight for all sequelae, corrected for
comorbidity. Disability weights are measured on a scale from 0
to 1, with 0 implying a state that is equivalent to full health and
1 a state equivalent to death. In order to generate an estimate of
total DALYs from 1990 to 2016, cause-specific years lived with
disability are summed with YLDs for each location and year.
For GWD, the following steps were taken to assign health states
to sequelae. First, the results of the literature review of Guinea
worm-related disability were used to identify sequelae related to
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Guinea worm emergence. For each sequela, an estimate of its
duration (as a fraction of one year) was multiplied across the
1,000 incidence draws to approximate prevalence. A simulation
was run to adjust disability weights for comorbidities for all causes
of the same sequelae across GBD18. For each sequela, the adjusted
disability weights were multiplied by prevalence and summed to
estimate DALYs for GWD by location and year for each draw.
From the 1,000 draws we calculated the point estimate as the
mean of the draws, and the 2.5th and 97.5th percentile draws used
to construct 95% uncertainty intervals (UI) for the estimation
years of 1990, 1995, 2000, 2005, 2010, and 2016, and then interpolated to create the entire 1990–2016 time series. The mean of
these annual estimates were summed to produce a total number
of DALYs attributable to GWD for 1990–2016.

We assumed that every case of GWD, using GBD health state
terminology, experienced “pain and disfigurement (moderate),”
and “musculoskeletal problems, lower limb (moderate)” for
a period of one month, followed by two months of “pain and disfigurement (mild).” Based on evidence from a study of long-term
disability conducted in Ghana6, we then assumed that 30% of all
case-patients then experienced “pain and disfigurement (mild)” for
an additional nine months (approximately a total year of disability) to account for longer-term disability associated with recovery.
The disability weights32 associated with these sequelae are as
follows: moderate disfigurement (with itch/pain), 0.188, 95% UI:
0.125–0.267; musculoskeletal problems, lower limbs (moderate), 0.079, 95% UI: 0.054–0.11; and mild disfigurement (with
itch/pain), 0.027, 95% UI: 0.015–0.042.

To estimate the number of DALYs that could have occurred in the
absence of eradication interventions four simple scenarios were
explored. First, the estimate of total DALYs was extrapolated
from 1990 to 2016 accounting for no other changes. Second,
DALYs from 1990 were extrapolated according to the annual
percentage change in country-level population growth using
GBD population estimates. A third scenario assumed declines in
DALYs occurred solely due to increased access to improved water
sources using the GBD 2016 national water coverage covariate
estimates from 1990–2016. In this scenario, the 1990 DALY estimate was reduced on an annual basis according to the increase
in the proportion of individuals with access to improved water
sources. Finally, to account for burden in the 1980s that GBD
results do not capture, the 1986 estimate of 3.5 million annual4
cases was held constant (of which 3.3 million cases estimated
for Africa27) and multiplied by the mean DALY per case from
GBD. The total number of DALYs predicted via GBD 2016 were
then subtracted from the total produced under each alternative
scenario to estimate the number of DALYs averted due to the
eradication campaign. For the 1986–2016 comparison, the
burden of GWD was assumed to decline 20% annually from
1987–1989 as case data from this period are limited and not
nationally representative for most locations.

Results of national-level GWD incidence estimates
Table 2 presents the total number of reported cases, modeled
cases, total DALYs, and DALYs per capita for 1990, as well as
the total country-specific DALYs for 2016 for comparison
(individual country models are presented in Supplementary
File 1). Overall, the GBD model predicts a total of approximately
1.6 million cases of GWD in 1990 and 27 cases in 2016 (compared to 25 cases reported in 2016). A total of 13 countries were
missing case reports for at least one year, and a total of
18 country-years of data were considered implausible (see
Supplementary File 1), accounting for the large difference in
reported and modeled case burden, particularly in 1990 and
1995. Had these possible outliers not been excluded, the model
would have predicted approximately 1.1 million cases of GWD
for 1990.

Results
Summary of data sources
A total of 21 countries were considered Guinea worm-endemic
as of 1990 (Figure 1)28. Sudan and South Sudan were modelled
separately in GBD for the entire time series even though they
were one country until 2011. A total of 729 country-year-specific
data points were identified (Supplementary File 1). The literature
review identified ten papers in which Guinea-worm-related morbidity was reported, summarized in Table 1. Sequelae associated
with GWD relate to the process of the worm’s emergence: pain
and itch as the worm exits the body, and the subsequent wound
that requires several weeks to heal and which can be further
complicated by abscesses and chronic ulcerations, joint and tissue
damage, as well as secondary infection in connective tissues29.
Pain and itch were widely reported during the worm’s emergence;
these persist for approximately one month until the worm exits the
body2. Several studies20,23,24,30,31 found that worms predominantly
emerge from the lower limbs, with reports ranging from 98%22
to 88%15 of all cases.

DALY estimates
The total DALYs attributed to GWD across all endemic countries in 1990 was 50,725 (95% UI: 35,300–69,200). From
1995 onward, the DALYs attributable to GWD dropped precipitously, with 1995 DALY estimates of 4,020 (95% UI: 2,750–5,530),
consistent with the expansion of eradication efforts in Africa
throughout the mid-1990s and 2000s. In 1990, the majority of the
DALYs occurred in Uganda (20,700; 95% UI: 14,300–28,200),
Nigeria (12,100; 95% UI: 8,300–16,600), and what is now South
Sudan (6,940; 95% UI: 4,810–9,390). In terms of DALYs per
100,000, estimates in 1990 were the highest in Uganda (118;
95% UI: 82–161), South Sudan (115; 95% UI: 80–156), and
Ghana (26; 95% UI: 18–36)). For comparison against other causes,
the 1990 DALY estimates per 100,000 indicate relative burden.
For example, in Ghana, the 1990 DALY estimate for lymphatic
filariasis was 80 (95% UI: 40-135) and schistosomiasis was
276 (95% UI: 182—435). In Nigeria, the DALYs for lymphatic
filariasis and schistosomiasis in 1990 were 208 (95% UI: 95—
377) and 301 (185—491), respectively (see GHDx search tool to
search results by country and year).
By interpolating the quinquennial DALY estimates, the total
cumulative DALYs due to GWD from 1990 to 2016 was approximately 129,355 (sum of the mean model prediction). In the
first scenario we tested in which the estimate of total DALYs
from 1990 (50,725.4 DALYs per year) is held constant through
2016, a cumulative 1.37 million DALYs could have occurred in
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Figure 1. Distribution of Guinea worm disease: 1990, 1995, 2000, 2005, 2010, and 2016. Distribution of GWD cases for 1990, 1995, 2000,
2005, 2010, and 2016. In dark grey, countries with ongoing transmission but no report; in light grey, countries never considered endemic; and
in shades of red total annual case counts, including countries with interruption of transmission that had imported cases.
Page 6 of 14

Gates Open Research 2018, 2:30 Last updated: 30 JUL 2018

Table 2. Country-specific burden estimates, comparing 1990 to 2016.
1990

2016

Total DALYs

DALYs per capita

Reported
Cases

Predicted
Cases†

Point
Estimate

Lower UI

Upper UI

Point
Estimate

Lower
UI

Upper
UI

DALYs
Total

Benin

37,414

37,410.5

1,139.6

783.8

1,563.8

23.2

15.9

31.8

-

Burkina Faso

42,187

42,190.1

1,277.2

874.9

1,753.4

14.6

9.9

20.0

-

Country

Cameroon

742

742.1

24.2

16.0

34.0

0.2

0.1

0.3

-

Central
African
Republic

*

188.5

6.2

3.4

10.1

0.2

0.1

0.3

-

Chad

*

4,912.1

151.2

101.6

215.2

2.6

1.7

3.7

0.5

1,360

21,323.4

652.2

436.8

897.3

5.4

3.6

7.5

-

Côte d’Ivoire
Ethiopia
Ghana
India
Kenya
Mali
Mauritania

2,333

2,332.7

76.1

51.5

106.4

0.2

0.1

0.2

0.09

123,793

123,810.0

3,804.7

2,616.5

5,210.4

26.0

18.0

35.7

-

4,798

4,800.3

156.4

105.9

217.9

0.02

0.01

0.03

-

6

61.4

2.0

1.2

3.1

0.01

0.01

0.01

-

884

21,723.36

660.0

454.2

906.1

7.8

5.4

10.1

0.0
-

8,036

8,034.3

246.2

167.4

339.0

12.5

8.5

17.2

*

61,698.8

1,896.3

1,280.2

2,618.4

24.3

16.4

33.6

Nigeria

394,082

394,078.7

12,067.6

8,345.6

16,593.6

12.8

8.9

17.7

-

Pakistan

160

160.1

5.2

3.4

7.5

0.004

0.003

0.01

-

Senegal

38

2,987.8

96.0

64.6

133.9

1.3

0.9

1.8

-

South
Sudan**

*

229,724.3

6,939.9

4,811.8

9,394.0

115.1

79.8

155.8

0.2

Sudan

*

8,116.9

260.7

174.1

363.8

1.4

1.0

1.9

-

Togo

3,042

16,659.15

510.2

344.7

704.5

13.7

9.2

18.9

-

Uganda

4,704

678,265.5

20,656.7

14,294.5

28,233.3

117.7

82.5

160.9

-

Yemen

*

2,562.8

82.1

43.2

141.1

0.7

0.4

1.2

-

623,579

1,661,782.7

50,725.4

35,265.3

69,197.0

-

-

-

0.9

Niger

Total

DALYs - Disability-adjusted life years
†Mean prediction from 1,000 draws.
*No data reported for 1990.
**South Sudan: Data for Sudan and South Sudan were disaggregated according to current national boundaries for the entire period 1990–2016 as
GBD estimates are generated for current political boundaries. We acknowledge that pre-2011, Sudan and South Sudan were not separate countries
and that pre-2006 Guinea worm eradication was implemented as a single national program33.

the absence of any change in GWD incidence. In the second scenario in which the 1990 DALY estimate is extrapolated according
to annual population growth, approximately 2 million DALYs
could have occurred. Third, accounting for secular improvements
in improved water source access we predict a total of 1.1 million
DALYs. Using these three scenarios, the number of DALYs averted
by the Guinea worm eradication campaign may be as low as
990,000 or as high as 1.89 million (see Table 3). Finally, by multiplying the mean DALYs per case generated by GBD (approximately 0.03) by the 1986 global case estimate of 3.5 million4,
we project a total of 106,836 DALYs per year for a total of 3.3
million DALYs that could have occurred from 1986–2016
had the 1986 burden remained constant. In this scenario, we

calculated 444,736 DALYs occurred under the eradication campaign, allowing for annual case reductions of 20% from 1987–1989
and GBD 2016 results for the period 1990–2016, resulting in
approximately 2.8 million DALYs averted from 1986–2016.

Discussion
This study summarizes the first model of GWD included in
the GBD study, estimating the burden of disease attributable to
Guinea worm from 1990 to 2016. In comparison to GBD results,
previously published studies present similar estimates of case burden, particularly for the early 1990s. The first model published
focused on incidence27 using reported case data corrected for
underreporting, estimating approximately 3.3 million incident cases
Page 7 of 14
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Table 3. Global Guinea worm disease disability-adjusted
life years (DALYs) averted comparing observed and
alternative scenarios.
Inputs
Estimated cases*
DALYs 1990*
DALYs observed 1990–2016*

DALYs
1,661,783
50,725
129,355

Annual 1990 burden remains constant

1,369,586

Increases with population growth

2,014,473

Changes in proportion with safe water coverage

1,119,703

DALYs averted: constant burden

1,240,231

DALYs averted: increases with population

1,885,118

DALYs averted: changes in safe water

990,348

*Using Global Burden of Disease 2016 results.

of GWD in Africa occurred in 1986 across 19 countries (Sudan
and South Sudan modeled as one country); including India and
Pakistan the estimate is 3.5 million cases for 19864. Another analysis, conducted in collaboration with the World Bank, estimated
approximately 1.5 million cases in 199034, a number similar
to the 1990 results herein. Other studies have presented the contribution of Guinea worm eradication in the context of Millennium
Development Goals35 and economic productivity gains34, and a
recent economic analysis calculates DALYs averted per dollar
as a metric to justify economic investment in eradication versus
control36. Here we similarly focus on DALYs averted as estimated by GBD 2016, with country-level DALYs presented for the
first time.
Whether disease eradication is motivated by an economic
and/or moral imperative, there are challenges inherent in quantifying the benefits attained. The DALY is a metric that enables
decision-makers and public health officials to compare across
different causes based on the disease experience, not only the
decline in cases. Our analysis includes a review of the scientific
literature on GWD, which is sparse and largely published before
1990. These studies may not be representative of the morbidity
experienced during the eradication campaign as case management
interventions reached scale. Since we also did not account for the
quantity of worm burden per case, our current DALY estimates
may underestimate the true burden of GWD, as evidence suggests severity of disability is related to the number of worms23.
Secondary complications associated with worm emergence that
persisted beyond a year post-emergence were not included, as
data on the long-term clinical outcomes of GWD were scarce.
Assumptions used in other analyses are based on single studies
with very small numbers36. For example, the estimate of 0.5%6
of all cases resulting in permanent disability results from a report
of one individual with permanent damage to a joint post worm
emergence from a sample of 195 individuals. Given the intensity
of community-based surveillance over the course of the eradication campaign, it might be possible to generate better parameters for GWD sequelae if detailed case data could be made
available.

Our analysis is the first to quantify the DALY burden of GWD
in the GBD 2016 framework and is subject to all GBD 2016specific limitations16–18,37. First, due to the scope of GBD, we were
only able to analyze from 1990 onward. It is plausible that case
data in the early 1990s do not capture the true incidence of GWD
in Africa due to under-reporting as many national eradication
programs had not reached full geographic coverage of endemic
areas. In terms of historical burden, this analysis also does not
account for the cases that were reported prior to 1990 from India
and Pakistan, countries which had begun eradication efforts in
1980 and 198738, respectively, much earlier than most of the other
countries (see SI for summary of national case searches). Had
our analysis accounted for a larger proportion of the historical
burden the number of DALYs averted by eradication campaign
interventions would be greater. Second, we attempted to correct
for under-reporting by omitting implausible annual country reports
which also could have introduced bias into the 1990 estimate.
Nevertheless, to ignore missing or implausible data points would
have otherwise introduced clear downward bias in our DALY
estimates, understating the true burden during this period. Prior
evidence acknowledges incomplete reporting39, and our analysis introduced greater levels of uncertainty for years in which
case estimates were missing or considered implausible. If
data points that were considered outliers had not been excluded
from the analysis, the total number of estimated cases would be
1.1 million, still far greater than the 623,579 cases reported by
WHO in 1990. This increase would account for missing case
data from Central African Republic, Chad, Niger, South Sudan,
Sudan and Yemen. Further, reliance on nationally representative
data did not enable us to account for the subnational distribution of disease, which may have resulted in over-prediction for
country-years that were missing data, notably for Uganda and
South Sudan.
Our model suggests that approximately 129,000 DALYs were
attributable to GWD for the entire period 1990–2016. As India
and Pakistan began national eradication efforts much earlier,
this burden largely occurred in Africa, with approximately 50,000
DALYs estimated in 1990 alone. A simple extrapolation of the
1990 mean DALY estimate would imply that 1.3 million DALYs
could have occurred in the absence of the eradication program
from 1990 onward. Accounting for population growth, that estimate grows to 2.0 million. Using only national level measures of
safe water quality to account for secular improvements that could
have eliminated transmission, this would suggest that approximately 990,000 DALYs have been averted over the past 27 years.
Although data availability pre-1990 limit our ability to construct complex alternative scenarios, the reduction in GWD case
reports outpaced national-level measures of water quality. There
was approximately an 80% reduction in reported cases of GWD
from 1990 to 1995, whereas the change in water access at the
national level (a GBD covariate) during this period ranged from
a decrease of 2% in coverage (Pakistan) to an increase of 23%
(Sudan), suggesting the eradication campaign interventions
such as filter cloths, health education and case containment
account for a large proportion of the reduction in burden.
While these alternative scenarios present simple estimates of
the possible GWD-related disability that has been prevented
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since 1990, future analyses with more detailed national-level
data could generate better estimates. It is likely our estimates of
DALYs averted under-estimate the true impact of eradication
as interventions in other high-burden settings like Ghana and
Nigeria were already underway. These estimates also do not
capture declines in GWD incidence occurring in India40 and
Pakistan41 in the 1980s, which combined reported between
20,000-30,000 cases per year combined. Using the 1986 estimate of 3.5 million cases4 would double the burden of GWD that
we estimated for 1990 and result in approximately 2.8 million
DALYs averted (assuming 1986 burden held constant) from
1986–2016.
The future of Guinea worm eradication will depend on a number
of factors, including elimination of infection in animals, surveillance in settings with insecurity, and maintenance of a programmatic infrastructure prior to elimination of transmission42.
Critics of eradication programs may claim that the “cost per
case” to sustain interventions at this late stage could be better
allocated to more pressing public health priorities. Nonetheless,
a recent economic analysis shows that eradication is still effective even at this late stage36. Should eradication efforts continue,
the small number of cases reported will not change the overall
results of historical DALYs estimated in this study, even if eradication takes decades. The costs expended versus DALYs saved
calculations will look increasingly disproportionate as annual
case totals continue to decline. By quantifying the contribution
of the global eradication program in terms of DALYs averted, we
demonstrate the huge benefit in the reduction of human
suffering. This study is important as it facilitates a more holistic assessment of the entire achievement of the campaign while
the final stubborn cases are eliminated.

Disclaimer
The findings and conclusions in this report are those of the
authors and do not necessarily represent the official position
of the Centers for Disease Control and Prevention.

Data availability
Data obtained using the Global Burden of Disease Exchange:
http://ghdx.healthdata.org/
A full set of extracted data is available from Open Science
Framework. Dataset 1: Guinea Worm dataset. http://doi.
org/10.17605/OSF.IO/B63JD43
This dataset is available under a CC0 1.0 Universal license.

Software availability
Code used to generate estimates is available from Github:
https://github.com/ihmeuw/ihme-modeling/tree/master/nonfatal_
code/ntd_guineaworm
Archived source code at the time of publication is available from
Zenodo: http://doi.org/10.5281/zenodo.128596244
The code is available under a CC by 4.0 license

Competing interests
No competing interests were disclosed.
Grant information
Bill & Melinda Gates Foundation [OPP1132415].
The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.

Supplementary material
Supplementary File 1 – Guinea worm case data by country or subnational division with country specific models results.
Click here to access the data.

References
1.

Hopkins DR: Disease eradication. N Engl J Med. 2013; 368(1): 54–63.
PubMed Abstract | Publisher Full Text

2.

Cairncross S, Muller R, Zagaria N: Dracunculiasis (Guinea worm disease) and
the eradication initiative. Clin Microbiol Rev. 2002; 15(2): 223–46.
PubMed Abstract | Publisher Full Text | Free Full Text

3.

Biswas G, Sankara DP, Agua-Agum J, et al.: Dracunculiasis (guinea worm
disease): eradication without a drug or a vaccine. Philos Trans R Soc Lond B
Biol Sci. 2013; 368(1623): 20120146.
PubMed Abstract | Publisher Full Text | Free Full Text

4.

Ruiz-Tiben E, Hopkins DR: Dracunculiasis (Guinea worm disease) eradication.
Adv Parasitol. 2006; 61: 275–309.
PubMed Abstract | Publisher Full Text

5.

Greenaway C: Dracunculiasis (guinea worm disease). CMAJ. 2004; 170(4):
495–500.
PubMed Abstract | Free Full Text

6.

7.

8.

9.

10.
11.

Hours M, Cairncross S: Long-term disability due to guinea worm disease. Trans
R Soc Trop Med Hyg. 1994; 88(5): 559–60.
PubMed Abstract | Publisher Full Text
Barry M: The tail end of guinea worm - global eradication without a drug or a
vaccine. N Engl J Med. 2007; 356(25): 2561–4.
PubMed Abstract | Publisher Full Text
Hopkins DR, Ruiz-Tiben E, Downs P, et al.: Dracunculiasis eradication:
neglected no longer. Am J Trop Med Hyg. 2008; 79(4): 474–9.
PubMed Abstract
Dracunculiasis eradication: global surveillance summary, 2016. Wkly Epidemiol
Rec. 2017; 92(20): 269–86.
PubMed Abstract
Fenner F: Smallpox and its eradication. 1988.
Reference Source
Thompson KM, Duintjer Tebbens RJ: Economic evaluation of the benefits and

Page 9 of 14

Gates Open Research 2018, 2:30 Last updated: 30 JUL 2018

costs of disease elimination and eradication initiatives. In: Cochi SL, Dowdle
WR, eds. Disease eradication in the 21st century. Cambridge: MIT Press; 2011;
115–32.
Reference Source

27.

12.

Emerson CI: The moral case for eradication. In: Cochi SL, Dowdle, WR, eds.
Disease Eradication in the 21st Centry. Cambridge: MIT Press; 2011; 103–14.
Reference Source

Watts SJ: Dracunculiasis in Africa in 1986: its geographic extent, incidence,
and at-risk population. Am J Trop Med Hyg. 1987; 37(1): 119–25.
PubMed Abstract | Publisher Full Text

28.

13.

Acharya AK, Murray CJL: Economic appraisal of eradication programs: the
question of infinite benefits. In: Dowdle WR, Hopkins DR eds. The Eradication of
Infectious Diseases. New York: John Wiley & Sons; 1998; 75–90.
Reference Source

Dracunculiasis. Global surveillance summary, 1990. Wkly Epidemiol Rec. 1991;
66: 225–30.
Reference Source

29.

14.

World Health Organization: Dracunculiasis Surveillance. Wkly Epidemiol Rec.
1982; 57: 65–72.

Muller R: Guinea worm disease: epidemiology, control, and treatment. Bull
World Health Organ. 1979; 57(5): 683–9.
PubMed Abstract | Free Full Text

30.

15.

Greenwood B, Greenwood A, Bradley A: Guinea worm infection in northern
Nigeria: reflections on a disease approaching eradication. Trop Med Int Health.
2017; 22(5): 558–566.
PubMed Abstract | Publisher Full Text | Free Full Text

Guthmann JP, Mercer AJ, Gandubert C, et al.: Guinea worm disease in Ayod,
Upper Nile Province, southern Sudan: a cross-sectional study. Trop Med Int
Health. 1996; 1(1): 117–23.
PubMed Abstract | Publisher Full Text

31.

16.

GBD 2016 DALYs and HALE Collaborators: Global, regional, and national
disability-adjusted life-years (DALYs) for 333 diseases and injuries and
healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a
systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;
390(10100): 1260–344.
PubMed Abstract | Publisher Full Text | Free Full Text

Lyons GR: Guineaworm infection in the Wa district of north-western Ghana.
Bull World Health Organ. 1972; 47(5): 601–10.
PubMed Abstract | Free Full Text

32.

Salomon JA, Haagsma JA, Davis A, et al.: Disability weights for the Global
Burden of Disease 2013 study. Lancet Glob Health. 2015; 3(11): e712–23.
PubMed Abstract | Publisher Full Text

33.

Jones AH, Becknell S, Withers PC, et al.: Logistics of Guinea worm disease
eradication in South Sudan. Am J Trop Med Hyg. 2014; 90(3): 393–401.
PubMed Abstract | Publisher Full Text | Free Full Text

34.

Kim A, Tandon A, Ruiz-Tiben E: Cost-benefit analysis of the global
dracunculiasis eradication campaign. 1997.
Publisher Full Text

35.

Callahan K, Bolton B, Hopkins DR, et al.: Contributions of the Guinea worm
disease eradication campaign toward achievement of the Millennium
Development Goals. PLoS Negl Trop Dis. 2013; 7(5): e2160.
PubMed Abstract | Publisher Full Text | Free Full Text

36.

Fitzpatrick C, Sankara DP, Agua JF, et al.: The cost-effectiveness of an
eradication programme in the end game: Evidence from guinea worm disease.
PLoS Negl Trop Dis. 2017; 11(10): e0005922.
PubMed Abstract | Publisher Full Text | Free Full Text

37.

GBD 2016 Causes of Death Collaborators: Global, regional, and national age-sex
specific mortality for 264 causes of death, 1980-2016: a systematic analysis for
the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 1151–210.
PubMed Abstract | Publisher Full Text | Free Full Text

38.

Centers for Disease Control and Prevention: Update: dracunculiasis eradication-worldwide, 1989. MMWR Morb Mortal Wkly Rep. 1990; 38: 882–5.
Reference Source

39.

Hopkins DR: Dracunculiasis: an eradicable scourge. Epidemiol Rev. 1983; 5: 208–19.
PubMed Abstract | Publisher Full Text

17.

GBD 2016 Mortality Collaborators: Global, regional, and national under-5
mortality, adult mortality, age-specific mortality, and life expectancy, 19702016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet. 2017; 390(10100): 1084–150.
PubMed Abstract | Publisher Full Text | Free Full Text

its epidemiology and impact on agricultural productivity. Am J Trop Med Hyg.
1975; 24(2): 243–9.
PubMed Abstract | Publisher Full Text

18.

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators: Global,
regional, and national incidence, prevalence, and years lived with disability for
328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis
for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):
1211–59.
PubMed Abstract | Publisher Full Text | Free Full Text

19.

Adeyeba OA, Kale OO: Epidemiology of dracunculiasis and its socio-economic
impact in a village in south-west Nigeria. West Afr J Med. 1991; 10(3–4): 208–15.
PubMed Abstract

20.

Ofoezie IE, Adeniyi IF: The prevalence and endemicity of dracunculiasis in
Akowide village, Oyo State, Nigeria. Ann Trop Med Parasitol. 1990; 84(2): 163–9.
PubMed Abstract | Publisher Full Text

21.

Smith GS, Blum D, Huttly SR, et al.: Disability from dracunculiasis: effect on
mobility. Ann Trop Med Parasitol. 1989; 83(2): 151–8.
PubMed Abstract | Publisher Full Text

22.

Okoye SN, Onwuliri CO, Anosike JC: A survey of predilection sites and degree
of disability associated with guineaworm (Dracunculus medinensis). Int J
Parasitol. 1995; 25(9): 1127–9.
PubMed Abstract | Publisher Full Text

40.

23.

Kale OO: The clinico-epidemiological profile of guinea worm in the Ibadan
district of Nigeria. Am J Trop Med Hyg. 1977; 26(2): 208–14.
PubMed Abstract | Publisher Full Text

Sharma R: India eradicates guinea worm disease. BMJ. 2000; 320(7236): 668.
PubMed Abstract | Free Full Text

41.

Omar MA, Gamba-Osiga A, Sufi QM, et al.: A survey of human dracunculiasis in
Kitgum District, Uganda. Ann Ig. 1993; 5(5): 313–20.
PubMed Abstract

Hopkins DR, Azam M, Ruiz-Tiben E, et al.: Eradication of dracunculiasis from
Pakistan. Lancet. 1995; 346(8975): 621–4.
PubMed Abstract | Publisher Full Text

42.

Molyneux D, Sankara DP: Guinea worm eradication: Progress and challengesshould we beware of the dog? PLoS Negl Trop Dis. 2017; 11(4): e0005495.
PubMed Abstract | Publisher Full Text | Free Full Text

43.

Cromwell E: Guinea Worm dataset. 2018.
Data Source

44.

Cromwell EA: Code for Guinea worm model GBD 2016. Zenodo. 2018.
Data Source

24.

25.

26.

Chippaux JP, Banzou A, Agbede K: [Social and economic impact of
dracunculosis: a longitudinal study carried out in 2 villages in Benin]. Bull
World Health Organ. 1992; 70(1): 73–8.
PubMed Abstract | Free Full Text
Belcher DW, Wurapa FK, Ward WB, et al.: Guinea worm in southern Ghana:

Page 10 of 14

Gates Open Research

Gates Open Research 2018, 2:30 Last updated: 30 JUL 2018

Open Peer Review
Current Referee Status:
Version 1
Referee Report 13 July 2018

doi:10.21956/gatesopenres.13900.r26527
Philip Downs
Sightsavers, Durham, NC, USA
Cromwell et al. establish an important metric to assess the impact of the Guinea worm eradication
programme and compare other disease and elimination programmes. As noted by the authors, the model
presented may under represent the impact on burden as earlier prevalence estimates are likely under
reported; estimates prior to 1990 put the prevalence of GWD closer to 3.5 million cases. A major
limitation is not accounting for the quantity of worm burden per case and accounting for the mental health
burden of the disease as part of sequelae. Article highlights the importance of all elimination programmes
to capture and publish parameters of disease sequelae as soon as possible.
Potential typo in one of the sentences - I believe the authors intended to mean unpublished in the
sentence "Our analysis includes a review of the scientific literature on GWD, which is sparse and largely
published before 1990."
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Thank you for the comment. We agree there is likely additional morbidity associated with the
number of worms per individual infected. Depending on the availability of data, it may be possible
to update the model in the GBD with an estimate of worm burden as it relates to either degree of
pain and limited mobility or duration of disease. Mental health outcomes are difficult to estimate in
this framework as data on morbidity due to Guinea worm disease likely come from cross-sectional
studies. In addition to attributing disability weights to mental health states, there is not enough
evidence to assign a duration to mental health outcomes associated with Guinea worm disease to
include in the calculation of a DALY.
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Under-reporting is discussed as an important limitation, and effort is make to evaluate how much cases
could have been under reported when it comes to estimating impact of GWEP.
Good review of information on sequelae. As they discuss, multiple worms could cause more sequelae by
hitting the same patient. Patients with multiple worms could have been under-reported, and multiple
worms could have been more frequent at the beginning of the GWEP which could make the quoted
results an under-estimate of the impact on burden. This should be explicitly modeled as part of their
sensitivity analysis.
In Chad, from 2000 to 2010, there must have been cases, but surveillance was missing them. It would be
more accurate to interpolate a burden of 10-20 cases during those years than to take the zero reports as
is. Alternatively, this could be reported as "*" as it is done in the appendix.
A note should be made about DRC and how the absence of reporting from that country without good
surveillance present may be masking some GW burden.
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We thank the reviewer for the comment. As we mention above, we will review data sources to
determine if worm burden can be included in future iterations of the model. While the point about
DRC is noted, we would need additional data sources from the Ministry of Health to re-consider the
geographic exclusions used in the analysis. The suggestion regarding Chad can be tested in a
subsequent iteration of the GBD.
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The article is very well written and the data presented on the burden of GWD accurately reflects the
situation in the known endemic countries to the best of my knowledge. Most of the global program data
before 1990 was mainly based on estimates from national health facility morbidity statistics or commonly
known as health facility reports. Obviously, these data sources have their own limitations as GWD or
Dracunculiasis could be misdiagnosed or misclassified during recording and reporting by health workers
or statisticians. The possibility of underreporting and overreporting exists at all levels of the health care
delivery nearly everywhere. On the other hand, since GW is a disease of poverty affecting the poorest of
the poor in very remote and underserved settings, it is highly likely that there could have been plenty of
cases missed or uncaptured by the health system due to lack access to the health service and hence
undermining the reported incidence/prevalence. I have noticed that the GBD estimates have taken this
scenario into account while calculating the annual incidence for each country. On the other hand, most of
the GWD burden reported after 1990 and most importantly after 1995 are likely to reflect the precise
picture of the GW situation in most of the endemic countries since there was a village-based surveillance
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picture of the GW situation in most of the endemic countries since there was a village-based surveillance
system established in nearly all countries where there was no civil strife occurring like in the case of
Sudan. I am in agreement with the way the DALYs were calculated. Most importantly, it is good that the
authors considered the GWD burden for the period 1990 - 2016. It would have been an over-estimate
had the authors considered the GWD burden for the period 1986 - 2016 to calculate the DALYs averted
by the global program. I am hesitant to attribute all the 80% GW case reduction observed during 1990 1995 to those soft interventions like filter distribution, health education and Abate application. I would say
that the reduction was mainly achieved due to improved reporting as a result of instituting trained village
based volunteers and thereby establishing effective village based surveillance system with robust
supervisory network from national level all the way down to district or county or LGA levels as the case
may be in each endemic country. Overall, I am appreciative of the work done by the authors. I have seen
firsthand the immense suffering and terrible consequences of this crippling disease and it is indeed worth
publishing this work to celebrate the great breakthrough attained in eradicating this dreadful disease.
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